Advertisement

FDA Approvals: Hep C Drug, Thyroid Cancer Drug, Avian Flu Vaccine — Physician’s First Watch

Medical News |
November 25, 2013

FDA Approvals: Hep C Drug, Thyroid Cancer Drug, Avian Flu Vaccine

By Amy Orciari Herman

Friday was a busy day at the FDA, with at least three new approvals:

Simeprevir: The protease inhibitor simeprevir (Olysio) is now approved to treat chronic hepatitis C virus infection. It's intended for use as part of a combination antiviral regimen (e.g., with peginterferon-alfa and ribavirin) in HCV-infected patients with compensated liver disease.

Sorafenib: Previously approved to treat certain kidney and liver cancers, sorafenib (Nexavar) may now be used in patients with metastatic, differentiated thyroid cancer. The drug is an oral kinase inhibitor.

Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted: The FDA approved the first adjuvanted vaccine for the prevention of H5N1 avian influenza. It's not intended for commercial use; rather, it will be included in the nation's stockpile for distribution by public health officials if the virus develops the ability to spread efficiently from human to human.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement